{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:43:18Z","timestamp":1789148598486,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","award":["16B100"],"award-info":[{"award-number":["16B100"]}],"id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds for Nanoscience Solutions","award":["1"],"award-info":[{"award-number":["1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Streptococcal infections are associated with life-threatening pneumonia and sepsis. The rise in antibiotic resistance calls for novel approaches to treat bacterial diseases. Anti-virulence strategies promote a natural way of pathogen clearance by eliminating the advantage provided to bacteria by their virulence factors. In contrast to antibiotics, anti-virulence agents are less likely to exert selective evolutionary pressure, which is a prerequisite for the development of drug resistance. As part of their virulence mechanism, many bacterial pathogens secrete cytolytic exotoxins (hemolysins) that destroy the host cell by destabilizing their plasma membrane. Liposomal nanotraps, mimicking plasmalemmal structures of host cells that are specifically targeted by bacterial toxins are being developed in order to neutralize-by competitive sequestration-numerous exotoxins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this study, the liposomal nanotrap technology is further developed to simultaneously neutralize the whole palette of cytolysins produced by\n                      <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                      ,\n                      <jats:italic>Streptococcus pyogenes<\/jats:italic>\n                      and\n                      <jats:italic>Streptococcus dysgalactiae subspecies equisimilis<\/jats:italic>\n                      -pathogens that can cause life-threatening streptococcal toxic shock syndrome. We show that the mixture of liposomes containing high amounts of cholesterol and liposomes composed exclusively of choline-containing phospholipids is fully protective against the combined action of exotoxins secreted by these pathogens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Unravelling the universal mechanisms that define targeting of host cells by streptococcal cytolysins paves the way for a broad-spectrum anti-toxin therapy that can be applied without a diagnostic delay for the treatment of bacterial infections including those caused by antibiotic-resistant pathogens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-021-00775-x","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T09:23:12Z","timestamp":1613553792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tailored liposomal nanotraps for the treatment of Streptococcal infections"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1426-1901","authenticated-orcid":false,"given":"Herv\u00e9","family":"Besan\u00e7on","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriia","family":"Babiychuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Larpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"K\u00f6ffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Schittny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Brockhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy J.","family":"Hathaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Sendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Draeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Babiychuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"775_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685\u201394.","journal-title":"Lancet Infect Dis."},{"key":"775_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13036-018-0138-z","volume":"13","author":"E Krueger","year":"2019","unstructured":"Krueger E, Brown AC. Inhibition of bacterial toxin recognition of membrane components as an anti- virulence strategy. J Biol Eng. 2019;13:1\u201314.","journal-title":"J Biol Eng."},{"key":"775_CR3","first-page":"277","volume":"40","author":"CL Ventola","year":"2015","unstructured":"Ventola CL. The antibiotic resistance crisis part 1: causes and threats. P&T. 2015;40:277\u201383.","journal-title":"P&T."},{"key":"775_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CPM.0000000000000255","volume":"25","author":"S Azeredo","year":"2018","unstructured":"Azeredo S, Perez A. CAL02 liposomes and other antitoxins: a new generation of anti-infectives. Top Pulm Med. 2018;25:84\u20138.","journal-title":"Top Pulm Med."},{"key":"775_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chom.2019.06.004","volume":"26","author":"U Theuretzbacher","year":"2019","unstructured":"Theuretzbacher U, Piddock LJ. Review non-traditional antibacterial therapeutic options and challenges. Cell Host Microbe. 2019;26:61\u201372.","journal-title":"Cell Host Microbe"},{"key":"775_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0955-0674(00)00109-5","volume":"12","author":"PO Falnes","year":"2000","unstructured":"Falnes PO, Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol. 2000;12:407\u201313.","journal-title":"Curr Opin Cell Biol"},{"key":"775_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mib.2003.12.007","volume":"7","author":"F Lafont","year":"2004","unstructured":"Lafont F, Abrami L, Van Der Goot FG. Bacterial subversion of lipid rafts. Curr Opin Microbiol. 2004;7:4\u201310.","journal-title":"Curr Opin Microbiol"},{"key":"775_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1042\/BC20050082","volume":"98","author":"B Geny","year":"2006","unstructured":"Geny B, Popoff MR. Bacterial protein toxins and lipids : pore formation or toxin entry into cells. Biol Cell. 2006;98:667\u201378.","journal-title":"Biol Cell"},{"key":"775_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2012.00075","volume":"2","author":"B Geissler","year":"2012","unstructured":"Geissler B. Bacterial toxin effector-membrane targeting: outside in, then back again. Front Cell Infect Microbiol. 2012;2:1\u201313.","journal-title":"Front Cell Infect Microbiol."},{"key":"775_CR10","first-page":"4024","volume":"51","author":"ME Ivarsson","year":"2012","unstructured":"Ivarsson ME, Leroux J, Castagner B. Targeting Bacterial Toxins Angewandte. Angew Rev. 2012;51:4024\u201345.","journal-title":"Targeting Bacterial Toxins Angewandte. Angew Rev."},{"key":"775_CR11","first-page":"1","volume":"1","author":"JK Rudkin","year":"2017","unstructured":"Rudkin JK, Mcloughlin RM, Preston A, Massey RC. Bacterial toxins: offensive, defensive, or something else altogether? PLoS Pathog. 2017;1:1\u201312.","journal-title":"PLoS Pathog"},{"key":"775_CR12","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1128\/IAI.73.10.6199-6209.2005","volume":"73","author":"RK Tweten","year":"2005","unstructured":"Tweten RK. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun. 2005;73:6199\u2013209.","journal-title":"Infect Immun"},{"key":"775_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pbiomolbio.2004.01.009","volume":"88","author":"MW Parker","year":"2005","unstructured":"Parker MW, Feil SC. Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol. 2005;88:91\u2013142.","journal-title":"Prog Biophys Mol Biol"},{"key":"775_CR14","first-page":"766","volume":"49","author":"CM Brandt","year":"2009","unstructured":"Brandt CM, Spellerberg B. Human infections due to Streptococcus dysgalactiae Subspecies equisimilis. Emerg Infect. 2009;49:766\u201372.","journal-title":"Emerg Infect."},{"key":"775_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nbt.3037","volume":"33","author":"BD Henry","year":"2015","unstructured":"Henry BD, Neill DR, Becker KA, Gore S, Bricio-Moreno L, Ziobro R, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33:81\u20138.","journal-title":"Nat Biotechnol"},{"key":"775_CR16","first-page":"2498","volume":"1860","author":"H Wolfmeier","year":"2016","unstructured":"Wolfmeier H, Radecke J, Schoenauer R, Koeffel R, Babiychuk VS, Dr\u00fccker P, et al. Active release of pneumolysin prepores and pores by mammalian cells undergoing a Streptococcus pneumoniae attack. BBA. 2016;1860:2498\u2013509.","journal-title":"BBA."},{"key":"775_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcdb.2015.10.016","volume":"45","author":"EB Babiychuk","year":"2015","unstructured":"Babiychuk EB, Draeger A. Seminars in cell & developmental biology defying death: cellular survival strategies following plasmalemmal injury by bacterial toxins. Semin Cell Dev Biol. 2015;45:39\u201347.","journal-title":"Semin Cell Dev Biol"},{"key":"775_CR18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1096\/fj.201901737RR","volume":"34","author":"Y Larpin","year":"2020","unstructured":"Larpin Y, Besan\u00e7on H, Iacovache MI, Babiychuk VS, Babiychuk EB, Zuber B, et al. Bacterial pore-forming toxin pneumolysin: cell membrane structure and microvesicle shedding capacity determines differential survival of immune cell types. FASEB J. 2020;34:1665\u201378.","journal-title":"FASEB J."},{"key":"775_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nnano.2013.54","volume":"8","author":"CJ Hu","year":"2013","unstructured":"Hu CJ, Fang RH, Copp J, Luk BT, Zhang L. A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol. 2013;8:336\u201340.","journal-title":"Nat Nanotechnol"},{"key":"775_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-016-0777-5","volume":"16","author":"D Baumgartner","year":"2016","unstructured":"Baumgartner D, Aebi S, Grandgirard D, Leib SL, Draeger A, Babiychuk E, et al. Clinical Streptococcus pneumoniae isolates induce differing CXCL8 responses from human nasopharyngeal epithelial cells which are reduced by liposomes. BMC Microbiol. 2016;16:1\u20137.","journal-title":"BMC Microbiol"},{"key":"775_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ebiom.2018.06.016","volume":"33","author":"H Wolfmeier","year":"2018","unstructured":"Wolfmeier H, Mansour SC, Liu LT, Pletzer D, Draeger A, Babiychuk EB, et al. EBioMedicine Liposomal Therapy Attenuates Dermonecrosis Induced by Community-Associated Methicillin-Resistant Staphylococcus aureus by Targeting \u03b1 -Type Phenol-Soluble Modulins and \u03b1 -Hemolysin. EBioMedicine. The Authors. 2018;33:211\u20137.","journal-title":"EBioMedicine. The Authors"},{"key":"775_CR22","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nri2402","volume":"8","author":"D Rittirsch","year":"2008","unstructured":"Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776\u201387.","journal-title":"Nat Rev Immunol"},{"key":"775_CR23","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1128\/AAC.00115-11","volume":"55","author":"CL Moore","year":"2011","unstructured":"Moore CL, Lu M, Cheema F, Osaki-kiyan P, Perri MB, Donabedian S, et al. Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool. Antimicrob Agents Chemother. 2011;55:4581\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"775_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1473-3099(18)30805-3","volume":"19","author":"P Laterre","year":"2019","unstructured":"Laterre P, Colin G, Dequin P, Dugernier T, Boulain T, Azeredo da Silveira S, et al. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2019;19:620\u201330.","journal-title":"Lancet Infect Dis."},{"key":"775_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrmicro2624","volume":"9","author":"EM Molloy","year":"2011","unstructured":"Molloy EM, Cotter PD, Hill C, Mitchell DA, Ross RP. Streptolysin S - like virulence factors: the continuing sagA. Nat Rev Microbiol. 2011;9:670\u201381.","journal-title":"Nat Rev Microbiol"},{"key":"775_CR26","first-page":"307","volume":"132","author":"C Loridan","year":"1986","unstructured":"Loridan C, Alouf JE. Purification of RNA-core induced streptolysin S, and isolation and haemolytic characteristics of the carrier-free toxin. J Gen Microbiol. 1986;132:307\u201315.","journal-title":"J Gen Microbiol"},{"key":"775_CR27","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1074\/jbc.R117.000582","volume":"293","author":"Y Yang","year":"2018","unstructured":"Yang Y, Lee M, Fairn GD. Phospholipid subcellular localization and dynamics. J Biol Chem. 2018;293:6230\u201340.","journal-title":"J Biol Chem"},{"key":"775_CR28","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1073\/pnas.77.7.4030","volume":"77","author":"KJ Hwang","year":"1980","unstructured":"Hwang KJ, Luk K-FS, Beaumier PL. Hepatic uptake and degradation of unilamellar sphingomyelin\/cholesterol liposomes: a kinetic study. Proc Natl Acad Sci USA. 1980;77:4030\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"775_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0005-2736(84)90273-6","volume":"774","author":"HH Spanjer","year":"1984","unstructured":"Spanjer HH, Morselt H, Scherphof GL. Lactosylceramide-induced stimulation of liposome uptake by Kupffer cells in vivo. BBA. 1984;774:49\u201355.","journal-title":"BBA."},{"key":"775_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0005-2736(86)90262-2","volume":"863","author":"HH Spanjer","year":"1986","unstructured":"Spanjer HH, van Galen M, Roerdink FH, Regts J, Scherphof GL. Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition. BBA. 1986;863:224\u201330.","journal-title":"BBA."},{"key":"775_CR31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/cmi.12531","volume":"17","author":"TC Barnett","year":"2015","unstructured":"Barnett TC, Cole JN, Rivera-hernandez T, Henningham A, Paton JC, Nizet V, et al. Microreview Streptococcal toxins: role in pathogenesis and disease. Cell Microbiol. 2015;17:1721\u201341.","journal-title":"Cell Microbiol"},{"key":"775_CR32","first-page":"1","volume":"1","author":"W Hynes","year":"2016","unstructured":"Hynes W, Sloan M. Secreted extracellular virulence factors. Streptococcus pyogenes Basic Biol maClin Manifest. 2016;1:1\u201340.","journal-title":"Streptococcus pyogenes Basic Biol maClin Manifest ."},{"key":"775_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrm2330","volume":"9","author":"Meer G Van","year":"2008","unstructured":"Van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9:112\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"775_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/femsre\/fuv008","volume":"40","author":"C Sohlenkamp","year":"2016","unstructured":"Sohlenkamp C, Geiger O. Bacterial membrane lipids: diversity in structures and pathways. FEMS Microbiol Rev. 2016;40:133\u201359.","journal-title":"FEMS Microbiol Rev"},{"key":"775_CR35","first-page":"439","volume":"131","author":"SA Rooney","year":"1984","unstructured":"Rooney SA. State of art the surfactant system and lung phospholipid biochemistry1-3. Am Rev Respir Dis. 1984;131:439\u201360.","journal-title":"Am Rev Respir Dis"},{"key":"775_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1086\/430625","volume":"192","author":"MR Wessels","year":"2005","unstructured":"Wessels MR, Streptolysin S. J Infect Dis. 2005;192:13\u20135.","journal-title":"J Infect Dis"},{"key":"775_CR37","doi-asserted-by":"publisher","first-page":"11227","DOI":"10.1073\/pnas.1413117111","volume":"111","author":"SCP Williams","year":"2014","unstructured":"Williams SCP. News feature: next-generation antibiotics. Proc Natl Acad Sci USA. 2014;111:11227\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"775_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrmicro3552","volume":"14","author":"GP Donaldson","year":"2016","unstructured":"Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016;14:20\u201332.","journal-title":"Nat Rev Microbiol"},{"key":"775_CR39","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1084\/jem.20182386","volume":"216","author":"HB Dodiya","year":"2019","unstructured":"Dodiya HB, Kuntz T, Shaik SM, Baufeld C, Leibowitz J, Zhang X, et al. Sex-specific effects of microbiome perturbations on cerebral Ab amyloidosis and microglia phenotypes. J Exp Med. 2019;216:1542\u201360.","journal-title":"J Exp Med"},{"key":"775_CR40","first-page":"4","volume":"147","author":"C Ruppen","year":"2017","unstructured":"Ruppen C, Rasmussen M, Casanova C, Sendi P. A 10-year observational study of Streptococcus dysgalactiae bacteraemia in adults: frequent occurrence among female intravenous drug users. Swiss Med Wkly. 2017;147:4\u20137.","journal-title":"Swiss Med Wkly."},{"key":"775_CR41","first-page":"681","volume":"8","author":"JV Jorge","year":"2017","unstructured":"Jorge JV, Magnus O, Buket B, Denedicte B-S, Michael RW. Binding of NAD\u2009+\u2009-glycohydrolase to streptolysin O stabilizes both Toxins and promotes virulence of group A Streptococcus. MBio. 2017;8:681\u20135.","journal-title":"MBio."},{"key":"775_CR42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-00775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-021-00775-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-00775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T03:04:16Z","timestamp":1674961456000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-021-00775-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1186\/s12951-021-00775-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-52770\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-52770\/v1","asserted-by":"object"}]},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"17 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript in accordance with ICMJE criteria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.B. and A.D. are inventors on a patent application pertaining to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}